<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7183126\results\search\disease\results.xml">
  <result pre="will exclude studies of patients with specific co-morbidities such as" exact="tuberculosis" post="or opportunistic infections. Primary outcomes will be &quot;the rate"/>
  <result pre="will first examine the therapeutic outcomes of DTG-use (e.g., viral" exact="suppression" post="and immunological response) and the rate of resistance to"/>
  <result pre="patients. Secondly, we will evaluate (a) the rate of viral" exact="suppression" post="according to clinical and biological parameters, (b) the effects"/>
  <result pre="will exclude studies of patients with specific co-morbidities such as" exact="tuberculosis" post="or opportunistic infections. Intervention DTG-based regimens will be our"/>
  <result pre="inhibitor-based regimens,�? and &quot;drug resistance according to viral subtypes/recombinants.�? Viral" exact="suppression" post="is defined as a plasma viral load less than"/>
  <result pre="and exclusion criteria) INSTI-based regimens Duration of INSTI-based regimens Viral" exact="suppression" post="Baseline viral load CD4-count following treatment INSTI drug resistance"/>
  <result pre="urban, rural), and study outcomes (i.e., the rate of viral" exact="suppression" post="and the level of drug resistance) using random intercept"/>
 </snippets>
</snippetsTree>
